SARS-CoV-2 and The Case for Empirical Treatment (Preprint)

2020 ◽  
Author(s):  
Richard P Bartlett ◽  
Alexandria Watkins
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
The United States ◽  
Type Ii Diabetes Mellitus ◽  
Outpatient Setting ◽  
Empirical Treatment ◽  
Residual Effects ◽  
Type Ii ◽  
West Texas

UNSTRUCTURED Background: This is an outpatient case study that examines two patients in the United States with unique cases that involve oncology, hypertension, Type II Diabetes Mellitus, and Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), also known as COVID-19. This case study involves two patients in the outpatient setting - treated via telemedicine, with laboratory-confirmed SARS-CoV-2 infection in the West Texas region between March 29th, 2020, and May 14th, 2020. Case Report: The first patient is a 63-year-old female, non-smoker, who is diagnosed with Waldenstrom’s Macroglobulinemia (2012) and Primary Cutaneous Marginal Zone Lymphoma (2020) and the second patient is a 38-year-old male, non-smoker, who has the following comorbidities: Type II Diabetes Mellitus (DM), hypertension, and gout. Both patients were empirically started on budesonide 0.5mg nebulizer twice daily, clarithromycin (Biaxin) 500mg tab twice daily for ten days, Zinc 50mg tab twice daily, and aspirin 81mg tab daily. Both patients have fully recovered with no residual effects. Conclusion: The goal is to call attention to the success of proactive, early empirical treatment, combining a classic corticosteroid (budesonide) administered via a nebulizer and an oral macrolide antibiotic known as clarithromycin (Biaxin).

scholarly journals Importance of Geospatial Heterogeneity in Chronic Disease Burden for Policy Planning in an Urban Setting Using a Case Study of Singapore

2021 ◽  
Vol 18 (9) ◽  
pp. 4406
Author(s):  
Ken Wei Tan ◽  
Joel R. Koo ◽  
Jue Tao Lim ◽  
Alex R. Cook ◽  
Borame L. Dickens
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Chronic Disease ◽  
Type Ii Diabetes ◽  
Census Data ◽  
Type Ii Diabetes Mellitus ◽  
Urban Setting ◽  
Type Ii

Chronic disease burdens continue to rise in highly dense urban environments where clustering of type II diabetes mellitus, acute myocardial infarction, stroke, or any combination of these three conditions is occurring. Many individuals suffering from these conditions will require longer-term care and access to clinics which specialize in managing their illness. With Singapore as a case study, we utilized census data in an agent-modeling approach at an individual level to estimate prevalence in 2020 and found high-risk clusters with >14,000 type II diabetes mellitus cases and 2000–2500 estimated stroke cases. For comorbidities, 10% of those with type II diabetes mellitus had a past acute myocardial infarction episode, while 6% had a past stroke. The western region of Singapore had the highest number of high-risk individuals at 173,000 with at least one chronic condition, followed by the east at 169,000 and the north with the least at 137,000. Such estimates can assist in healthcare resource planning, which requires these spatial distributions for evidence-based policymaking and to investigate why such heterogeneities exist. The methodologies presented can be utilized within any urban setting where census data exists.

scholarly journals Screening for Type II Diabetes Mellitus in the United States: The Present and the Future

2016 ◽  
Vol 9 ◽  
pp. CMED.S38247 ◽  
Author(s):  
Ayesha Abid ◽  
Shahla Ahmad ◽  
Abdul Waheed
Keyword(s):  
Diabetes Mellitus ◽  
United States ◽  
Type Ii Diabetes ◽  
The United States ◽  
Type Ii Diabetes Mellitus ◽  
Screening Tests ◽  
Type Ii ◽  
Screening Practices ◽  
Number Of Individuals ◽  
Current Screening

The number of individuals being diagnosed with type II diabetes in the United States is increasing. The screening tests for diabetes are able to detect the vast majority of diabetics. However, they do not represent the high-risk individuals who may be prone to diabetes at an earlier age. This brief communication looks at the current screening practices and the gaps in the guidelines.

scholarly journals 340. Prevalence of Type II Diabetes Mellitus Among Patients Living with HIV in the United States

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S180-S181
Author(s):  
Morgan Birabaharan ◽  
Andrew Strunk ◽  
Amit Garg ◽  
Stefan Hagmann
Keyword(s):  
Diabetes Mellitus ◽  
United States ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
The United States ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Living With Hiv

Abstract Background An aging HIV-infected population has growing recognition for its increasing prevalence of type 2 diabetes mellitus (T2DM). Most studies of T2DM prevalence among patients living with HIV involve selected samples and/or small cohorts which limit generalizability. We sought to evaluate the overall prevalence of T2DM among patients living with HIV in the United States as well as within specific demographic subgroups. Methods A cross-sectional analysis was performed using a large, multi-institutional database (Explorys), where clinical information across 27 healthcare networks are matched and standardized to create longitudinal records for each unique patient. At present, the database contains 63 million unique lives, representing 18% of the population across all 4 census regions of the United States. Patients with all types of insurance as well as those who are self-pay are represented. The analysis included adult patients with an active status in the database during April 2014- April 2019 who, not missing data on age, gender, race, and body mass index. The Systematized Nomenclature of Medicine—Clinical Terms (SNOMED-CT) of “Human Immunodeficiency Virus,” “diabetes mellitus type 2,” “disorder due to type 2 diabetes mellitus,” and “Type II diabetes mellitus uncontrolled” were used to identify patients with HIV and T2DM. Results We identified 90,900 patients with HIV. The overall prevalence of T2DM among patients with HIV was 22.1% (20,080/90,900) compared with 14.9% (2,679,490/17,946,580) in the general population. In subgroup analysis, the prevalence of T2DM was highest among patients with HIV who were female, older, other race, obese, hypertensive, hyperlipidemic, smokers, alcoholics, and those with a history of hepatitis C infection. Patients with no exposure to antiretroviral therapy (ART) had higher prevalence of T2DM than those with exposure (24.9% vs. 17.6%). Conclusion In this US population-based study, we found 1 in 5 people living with HIV had prevalent T2DM. In addition, we observed that HIV-associated T2DM may not depend on chronic ART exposure. Physicians caring for patients with HIV should be aware of the association and should monitor for signs and symptoms of T2DM. Disclosures All authors: No reported disclosures.

scholarly journals Management of Madhumeha with Vallipanchmool Churna – A Case Study.

2021 ◽  
Vol 5 (04) ◽  
Author(s):  
Payal Thakur Payal
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Single Case ◽  
Type Ii Diabetes Mellitus ◽  
Ayurvedic Medicine ◽  
Type Ii ◽  
Major Health Problem ◽  
Major Health ◽  
Modern System

Diabetes Mellitus is a major health problem in the whole world. In spite of tremendous advancements of the modern system of medicine as OAD (oral anti-diabetic drug) and insulin therapy, to date, an ideal drug that can control hyperglycemia is still a distant dream. It has been a challenge for Ayurveda to search for additional effective solutions resulting in the better management of the disease. There is a need for effective, safe and potent medicine which can control hyperglycemia related to type II diabetes and has no side effects.  In this case study, we used Ayurvedic medicine ‘Vallipanchmoolchurna’ mentioned in Sushruta Samhita in a single case study which was done on the use of  Vallipanchmool churna on type II Diabetes Mellitus. A significant reduction was seen in blood sugar level fasting and post-meal.

Sign in / Sign up

Export Citation Format

Share Document